LONDON: Moderna Inc.
said on Thursday the Covid-19 shot was around 93% effectively four to six months after the second dose, showed almost all changes from the efficacy of 94% reported in the original clinical trial.
Which compares with data released by Rivals Pfizer Inc.
and Bionech SE last week where they suggested the efficacy of their vaccine decreases by about 6% every two months, decreasing around 84% six months after the second shot.
Modern vaccines and pfizer-biontech are based on Messenger RNA technology (MRNA).
“We are very pleased that the efficacy of our Covid-19 vaccine is stable at 93% from four to six months,” said Chief Executive Moderna Stéphane Bancel in a statement.
“This strong duration will benefit hundreds of millions of people who have been dosed at this time with a modern vaccine.” Moderna posted a second quarter sales of $ 4.4 billion, slightly above the estimated average of $ 4.2 billion taken from 10 analysts surveyed by refinitiv.
Covid-19 shots are the company’s first official product and sales of only $ 67 million in the same period last year.
The company recorded a net profit of $ 2.78 billion in the quarter or $ 6.46 per share, beating expectations of $ 2.46 billion or $ 5.96 per share.
Durable vaccines can mean the recipient might be able to wait longer among shots if they ultimately need a booster or not even need additional doses to prevent Covid-19.
The public health authority around the world wrestle with a very transmitting Delta variant is debating whether the additional dose of the Covid-19 vaccine is safe, effective and necessary.
Pfizer plans to request authorization for the three vaccine shots later this month, and some countries – like Israel – have started or planned to immediately start a shot to older or vulnerable people.
Moderna said its sustainable research of three different booster candidates induced strong antibody responses to the variant of important concerns.
This includes the Gamma variant, Beta and Delta which was first identified in Brazil, South Africa and India.
It was said to neutralize the level of antibodies after the encouragement approached them observed after the shot of the two vaccines.
For this year, Moderna has signed a $ 20 billion in sales and hopes to produce between 800 million and 1 billion doses of vaccines.
It has an agreement for $ 12 billion in 2022, with the option for around $ 8 billion.
It hopes to produce between 2 and 3 billion doses of next year.
The company has not been able to compensate for a much larger rival pfizer production, which expects to produce as many as 3 billion doses of vaccine this year, and expect 2021 vaccine sales to be developed with bionechs of up to $ 33.5 billion.
The modern vaccine is permitted for emergency use in adults in the United States in December and has since been cleaned for emergency or conditional use in adults in more than 50 countries.
The company began a full submission process with the provision of US food and medicine in June and hoped to complete its submission in August.